Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2/neu overexpression

Márquez-Garbán, Diana C.; Gorrin-Rivas, Manuel J.; Chen, Hsiao-Wang; Sterling, Colin; Elashoff, David; Hamilton, Nalo; Pietras, Richard J.

doi:10.1016/j.canlet.2019.02.009

Cited by 20 publications

(12 citation statements)

References 68 publications

(146 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of squalamine with cisplatin is effective in ovarian cancer, including those with HER-2 overexpression, which is resistant to cisplatin monotherapy [150]. Furthermore, squalamine inhibits the growth of HER-2-negative breast cancer MCF-7 and HER-2-positive MCF-7 in combination with trastuzumab by blocking the action of the endogenous activator of angiogenesis VEGF [163].…”

Section: Antiangiogenic and Antitumor Activitymentioning

confidence: 99%

From Marine Metabolites to the Drugs of the Future: Squalamine, Trodusquemine, Their Steroid and Triterpene Analogues

Казакова

Giniyatullina

Babkov

et al. 2022

IJMS

View full text Add to dashboard Cite

This review comprehensively describes the recent advances in the synthesis and pharmacological evaluation of steroid polyamines squalamine, trodusquemine, ceragenins, claramine, and their diverse analogs and derivatives, with a special focus on their complete synthesis from cholic acids, as well as an antibacterial and antiviral, neuroprotective, antiangiogenic, antitumor, antiobesity and weight-loss activity, antiatherogenic, regenerative, and anxiolytic properties. Trodusquemine is the most-studied small-molecule allosteric PTP1B inhibitor. The discovery of squalamine as the first representative of a previously unknown class of natural antibiotics of animal origin stimulated extensive research of terpenoids (especially triterpenoids) comprising polyamine fragments. During the last decade, this new class of biologically active semisynthetic natural product derivatives demonstrated the possibility to form supramolecular networks, which opens up many possibilities for the use of such structures for drug delivery systems in serum or other body fluids.

show abstract

Section: Antiangiogenic and Antitumor Activitymentioning

confidence: 99%

From Marine Metabolites to the Drugs of the Future: Squalamine, Trodusquemine, Their Steroid and Triterpene Analogues

Казакова

Giniyatullina

Babkov

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…There is no globally accepted method to determine its status. This gene encodes a homologous to epidermal growth factor receptor (11,12).…”

Section: Introductionmentioning

confidence: 99%

Comparison of Her-2/Neu Gene Amplification or Expression between IHC and FISH in BC

Zhang

Gong

2022

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

This study aimed to analyze and compare the application of FISH and IHC in BC tissue Her-2 / neu gene amplification or expression. For this purpose, 110 patients with BC were selected. FISH and IHC were performed on the BC tissues that were surgically removed, and the results were compared and analyzed. The results showed that in 110 BC tissues, the expression of HER-2 protein was (+++) 25 cases (22.73%); (++) 44 cases (40%); (+) 26 cases (23.64%); (1) 15 cases (13.64%). There were 42 cases of HER-2 gene amplification in 110 BC tissues, and 68 cases had no amplification. IHC test positive (+++) is consistent with FISH positive coincidence rate, IHC test negative (+/-) is consistent with FISH negative coincidence rate, IHC test suspicious positive (++) compared with the FISH result, the difference is statistically significant. However, the total coincidence rate between IHC test results and FISH test results was 89.29 (25/28), and the two test methods were positively correlated. Generally, IHC positive and negative expressions are in good agreement with FISH test results. The suspected positive expression of IHC is inconsistent with the FISH test result, suggesting that the IHC test is suspicious, and the positive specimens need to be tested by FISH.

show abstract

“…Their determinative role was demonstrated in breast cancer and led to the appearance of specific treatments based on inhibition and inactivation of these receptors ( 7 ). HER-2 proto-oncogene is a 185-kDa transmembrane glycoprotein with tyrosine-specific kinase activity ( 8 ). Its gene (HER-2/neu) locates on chromosome 17 (17q12–q21.32) ( 9 ).…”

Section: Introductionmentioning

confidence: 99%

Investigation of HER-2 expression and its Correlation with clinicopathological parameters and overall survival of esophageal squamous cell carcinoma patients

et al. 2020

View full text Add to dashboard Cite

Human epidermal growth factor receptor 2, Squamous cell carcinoma Scan to discover online Background & Objective: Human epidermal growth factor receptor 2 (HER-2) exhibits a vast range of expression in esophageal squamous cell carcinoma (ESCC) patients as a biomarker. This paper aimed to investigate HER-2 expression and clinicopathological parameters of esophageal SCC. Methods: HER-2 expression was assessed in 102 ESCC patients by immunohistochemistry. The HER-2 staining intensity , according to the Gastric HER2 Biomarker1.0.0.1 version of the college of American pathologists (CAP) protocol for gastric and gastroesophageal junction cancers, was graded as 0 (no reactivity in any of the cancer cells' membranes); 1+ (pale or hardly noticeable reactivity in the membrane of cancer cells' cluster [≥ 5 neoplastic cells] regardless of the positive cancer cells' percentage); 2+ (weak-to-moderate complete, basolateral, or lateral membranous reactivity regardless of the positive cancer cells' percentage); and 3+ (strong complete, basolateral, or lateral reactivity in the membrane of the cancer cell cluster regardless of the positive cancer cells' percentage).In this regard, 3+ scored samples were considered as positive. If HER-2 expression was scored 2+, an additional fluorescence in situ hybridization (FISH) was performed. Fisher's exact test was employed for investigating the correlation of HER-2 expression status with patients' clinicopathological characteristics (including age, gender, tumor location, stage, grade, infiltration level, venous invasion, lymphatic invasion, and tumor recurrence). Kaplan-Meier analysis was done for the patients' survival assessments. Results: Five patients (~5%) were HER-2 positive and no significant association was observed between HER-2 expression and clinicopathological properties. In addition, HER-2 expression status exhibited no significant association with the patients' overall survival (P=0.9299). Conclusion: HER-2 is not a suitable prognostic biomarker for Iranian ESCC patients.

show abstract

Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2/neu overexpression

Cited by 20 publications

References 68 publications

From Marine Metabolites to the Drugs of the Future: Squalamine, Trodusquemine, Their Steroid and Triterpene Analogues

From Marine Metabolites to the Drugs of the Future: Squalamine, Trodusquemine, Their Steroid and Triterpene Analogues

Comparison of Her-2/Neu Gene Amplification or Expression between IHC and FISH in BC

Investigation of HER-2 expression and its Correlation with clinicopathological parameters and overall survival of esophageal squamous cell carcinoma patients

Contact Info

Product

Resources

About